



Pompe Global Program Update, April 23, 2010

Genzyme would like to provide a brief update to the global Pompe community related to some recent delays in shipments of Myozyme[®] (αglucosidase alfa) produced at the 4000 L manufacturing scale in our Geel, Belgium facility. This scale of product currently supplies the majority of countries worldwide and the ATAP program in the United States. These delays were neither related to a supply shortage of Myozyme nor Genzyme's recent announcement of production issues at the Allston facility, as Myozyme 4000 L is not produced in that facility.

Several weeks ago, a mechanical problem at our Geel, Belgium facility was discovered during routine plant maintenance. The faulty equipment was immediately repaired. However, upon identifying this mechanical problem, product shipments were suspended as a precautionary measure while we conducted a quality assurance assessment of the situation. Genzyme notified relevant regulatory authorities of the situation and provided them with our completed assessment, which concluded that there were no safety concerns with the product. Shipments of Myozyme resumed the week of April 6th. This event may have resulted in patients in a limited number of countries to reschedule infusions.

Soon after shipping had resumed, as many of you are aware, a volcano in Iceland erupted and created an ash cloud that shut down the majority of flights in Europe for several days. This resulted in a second suspension of product shipments, as Genzyme distributes Myozyme produced in Geel from distribution facilities in England and Ireland. The air space is now cleared for air travel and we have resumed shipments.

Patients who have not been contacted by their infusion site to reschedule their infusions can assume that they were not impacted by the shipping delays. We apologize for any inconvenience caused to physicians and patients during these past several weeks.